Acute myeloid leukemia is one of the childhood cancers with the worst prognosis. While chemotherapy and stem cell transplantation are still the standard of care, targeted therapies such gemtuzumab ozogamicin (G.O.) have also emerged. At UF, Jatinder Lamba’s team previously discovered that a genetic variation affects how patients respond to G.O.

In a new study, the researchers used artificial intelligence to identify the combinations of genetic variants that best predicted outcomes in patients that received standard chemotherapy and G.O. They also developed a genetic score to predict patient outcomes with the targeted drug treatment.

• Jatinder Lamba